The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
another issue is it's a new phenomenon called u glycemic decay u glycemic diabetic ketoacidosis and we're seeing this in these sodium-glucose cotransport ur inhibitors these sglt2 inhibitors and it's a very bizarre phenomenon but in people with type 1 diabetes who go on these sodium-glucose cotransport or inhibitors they can get a strange form of decay where their glucose is not elevated
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.